一、基本信息

姓名：芮蒙杰

通讯地址：江苏省镇江市学府路301号 江苏大学药学院（邮编：212013）

办公室：江苏大学药学院2213室

电子邮件：mjrui@ujs.edu.cn

二、个人简介

芮蒙杰，江苏大学药学院药剂学系副教授、研究生导师，上海交通大学生物医学工程博士。研究融合药剂学、生物医学工程与人工智能，主要开展治疗性多肽与小分子设计、药物靶点及协同组合预测、制剂处方优化，以及仿生和刺激响应型纳米递药系统研究，面向肿瘤治疗、免疫治疗、骨关节炎及中药多组分现代制剂应用。围绕仿生脂蛋白介导的药物与核酸递送、肿瘤响应性多肽和联合治疗开展系列研究，主持国家自然科学基金青年项目及江苏省自然科学基金青年、面上项目等，成果发表于Drug Delivery、Molecular Pharmaceutics等期刊。

三、教育经历

2008.09—2012.12｜上海交通大学生命科学技术学院，生物医学工程专业｜博士（导师：徐宇虹教授）

2004.09—2008.06｜上海交通大学生命科学技术学院，生物工程专业｜工学学士

四、工作经历

2017.05—至今｜江苏大学药学院药剂学系｜副教授

2013.03—2017.04｜江苏大学药学院药剂学系｜讲师

五、研究方向

1.人工智能辅助药物发现与计算药剂学：应用机器学习、深度学习和分子模拟开展药物靶点相互作用、药物协同作用及候选分子预测，并优化制剂处方与工艺。

2.治疗性多肽与肿瘤免疫治疗：围绕PD-1/PD-L1、Notch/RBPJ等相关通路设计多肽及小分子抑制剂，研究肿瘤激活型溶瘤多肽与免疫调节多肽。

3.仿生与刺激响应型纳米药物：构建仿生脂蛋白、脂质盘、脂质体、多囊脂质体、聚合物纳米粒及聚合物囊泡，用于多肽、核酸、小分子和多组分药物的精准联合递送。

4.联合治疗与中药多组分现代制剂：通过计算方法筛选协同药物组合及配比，结合机制验证与制剂设计，开展中药活性成分联合治疗研究。

六、科研成果

6.1 科研项目

1. 2018.07—2021.06｜江苏省自然科学基金面上项目“应激响应蛋白模拟系统用于活性生物大分子的靶向递送及抗肿瘤机制研究”（项目编号：BK20181445）｜江苏省自然科学基金｜主持

2. 2015.01—2017.12｜国家自然科学基金青年科学基金项目“二聚肽介导的多功能脂质载体靶向联合治疗乳腺癌的应用及其机制研究”（项目编号：81402880）｜国家自然科学基金委员会｜主持

3. 2013.07—2016.07｜江苏省自然科学基金青年项目“HDL纳米粒作为肝癌靶向共输送载体的构建及机制的研究”（项目编号：BK20130541）｜江苏省自然科学基金｜主持

6.2 学术论文

期刊论文

[1] RUI M, FANG L, JIA M, et al. Tumor microenvironment-responsive conformational activation of apoA-I mimetic peptides for targeted cancer therapy[J]. Drug Delivery, 2026, 33(1): 2604086. DOI: 10.1080/10717544.2025.2604086.

[2] RUI M, TANG H, GAO L, et al. pH-responsive polymeric nanoparticles for peptide delivery: Synergistic STING pathway activation enhances tumor immunotherapy[J]. International Journal of Pharmaceutics X, 2025, 10: 100412. DOI: 10.1016/j.ijpx.2025.100412.

[3] RUI M, WANG L, MI K, et al. Co-delivery of anti-inflammatory and antioxidant agents via polymersomes for osteoarthritis therapy[J]. Frontiers in Pharmacology, 2025, 16: 1635761. DOI: 10.3389/fphar.2025.1635761.

[4] RUI M, SU Y, TANG H, et al. Computational Design and Optimization of Multi-Compound Multivesicular Liposomes for Co-Delivery of Traditional Chinese Medicine Compounds[J]. AAPS PharmSciTech, 2025, 26(2): 61. DOI: 10.1208/s12249-025-03042-6.

[5] FENG C, CHENG J, SUN M, QIAO C, FENG Q, FANG N, GE Y, RUI M. Artificial intelligence-driven identification and mechanistic exploration of synergistic anti-breast cancer compound combinations from Prunella vulgaris L.-Taraxacum mongolicum Hand.-Mazz. herb pair[J]. Frontiers in Pharmacology, 2025, 15: 1522787. DOI: 10.3389/fphar.2024.1522787.

[6] JI W, SHE S, QIAO C, FENG Q, RUI M, XU X, FENG C. A general prediction model for compound-protein interactions based on deep learning[J]. Frontiers in Pharmacology, 2024, 15: 1465890. DOI: 10.3389/fphar.2024.1465890.

[7] RUI M, ZHANG W, MI K, et al. Design and evaluation of α-helix-based peptide inhibitors for blocking PD-1/PD-L1 interaction[J]. International Journal of Biological Macromolecules, 2023, 253(Pt 2): 126811. DOI: 10.1016/j.ijbiomac.2023.126811.

[8] SHE S, CHEN H, JI W, SUN M, CHENG J, RUI M, FENG C. Deep learning-based multi-drug synergy prediction model for individually tailored anti-cancer therapies[J]. Frontiers in Pharmacology, 2022, 13: 1032875. DOI: 10.3389/fphar.2022.1032875.

[9] RUI M, CAI M, ZHOU Y, et al. Identification of Potential RBPJ-Specific Inhibitors for Blocking Notch Signaling in Breast Cancer Using a Drug Repurposing Strategy[J]. Pharmaceuticals, 2022, 15(5): 556. DOI: 10.3390/ph15050556.

[10] RUI M, PANG H, JI W, et al. Development of simultaneous interaction prediction approach (SiPA) for the expansion of interaction network of traditional Chinese medicine[J]. Chinese Medicine, 2020, 15: 90. DOI: 10.1186/s13020-020-00369-z.

[11] FENG C, ZHANG H, CHEN J, WANG S, XIN Y, QU Y, ZHANG Q, JI W, YAMASHITA F, RUI M. Ratiometric Co-Encapsulation and Co-Delivery of Doxorubicin and Paclitaxel by Tumor-Targeted Lipodisks for Combination Therapy of Breast Cancer[J]. International Journal of Pharmaceutics, 2019, 560: 191-204.

[12] FENG C, YUAN X, CHU K, ZHANG H, JI W, RUI M. Preparation and Optimization of Poly (Lactic Acid) Nanoparticles Loaded with Fisetin to Improve Anti-Cancer Therapy[J]. International Journal of Biological Macromolecules, 2019, 125: 700-710.

[13] ZHANG Q, ZHANG J, XUE S, RUI M, GAO B, LI A, BAI J, YIN Z, ANOCHIE E M. Enhanced Enantioselectivity of Native α-Cyclodextrins by the Synergy of Chiral Ionic Liquids in Capillary Electrophoresis[J]. Journal of Separation Science, 2018, 41(24): 4525-4532.

[14] TANG H, RUI M, YU C, CHU T, LI C, ZHAN Z, CAO H, LI H, LIU Z, SHEN H. Nanotechnology in Generation and Biomedical Application of Induced Pluripotent Stem Cells[J]. Nano Life, 2018, 8(4): 1841002.

[15] FENG C, RUI M, SHEN H, XIN Y, ZHANG J, LI J, YUE L, LAI W, XU X. Tumor-specific delivery of doxorubicin through conjugation of pH-responsive peptide for overcoming drug resistance in cancer[J]. International Journal of Pharmaceutics, 2017, 528(1-2): 322-333.

[16] RUI M, XIN Y, LI R, GE Y, FENG C, XU X. Targeted Biomimetic Nanoparticles for Synergistic Combination Chemotherapy of Paclitaxel and Doxorubicin[J]. Molecular Pharmaceutics, 2017, 14(1): 107-123.

[17] RUI M, QU Y, GAO T, GE Y, FENG C, XU X. Simultaneous delivery of anti-miR21 with doxorubicin prodrug by mimetic lipoprotein nanoparticles for synergistic effect against drug resistance in cancer cells[J]. International Journal of Nanomedicine, 2017, 12: 217-237.

[18] TANG H, CHEN X, RUI M, SUN W, CHEN J, PENG J, XU Y. Effects of surface displayed targeting ligand GE11 on liposome distribution and extravasation in tumor[J]. Molecular Pharmaceutics, 2014, 11(10): 3242-3250.

[19] RUI M, TANG H, LI Y, WEI X, XU Y. Recombinant High Density Lipoprotein Nanoparticles for Target-Specific Delivery of siRNA[J]. Pharmaceutical Research, 2013, 30(5): 1203-1214.

[20] LI Y, RUI M, TANG H, XU Y. The distribution and cell uptake of ApoA1 modified lipid carriers of siRNA in mouse liver in vivo[J]. Asian Journal of Pharmaceutical Sciences, 2013, 8: 228-233.

[21] RUI M, GUO W, DING Q, WEI X, XU J, XU Y. Recombinant high-density lipoprotein nanoparticles containing gadolinium-labeled cholesterol for morphologic and functional magnetic resonance imaging of the liver[J]. International Journal of Nanomedicine, 2012, 7: 3751-3768.

[22] ZHANG X, YANG H, GU K, CHEN J, RUI M, JIANG G L. In vitro and in vivo study of a nanoliposomal cisplatin as a radiosensitizer[J]. International Journal of Nanomedicine, 2011, 6: 437-444.

[23] MAI J, SONG S, RUI M, LIU D, DING Q, PENG J, XU Y. A synthetic peptide mediated active targeting of cisplatin liposomes to Tie2 expressing cells[J]. Journal of Controlled Release, 2009, 139(3): 174-181.